Short answer
Nkarta, Inc. (NKTX) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Webcast scheduled November 9, 2026 at 8:00 a.m. Eastern Time.
Nkarta, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Webcast scheduled November 9, 2026 at 8:00 a.m. Eastern Time
- Initial clinical data from NKX019’s Ntrust program in myositis and systemic sclerosis
- ACR Convergence 2026 presentation creates a near-term clinical catalyst for Nkarta shares
Item EX-99.1 · Exhibit EX-99.1
- Webcast scheduled November 9, 2026 at 8:00 a.m. ET to present initial NKX019 clinical data at ACR Convergence 2026
- Data cover Ntrust trials in myositis and systemic sclerosis, creating a near-term clinical catalyst for NKTX shares
- Ntrust-1 and Ntrust-2 evaluate safety and remission potential through CD19-targeted B-cell elimination
- Trials enroll up to 12 patients per dose level per disease indication, including additional autoimmune diseases
- NKX019 uses three-dose cycles after lymphodepletion, testing off-the-shelf CAR-NK therapy without exogenous cytokine support
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nkarta, Inc. 8-K filings
Get the next NKTX 8-K as it lands
Follow NKTX for push alerts, or ask the research agent what this filing means.